医学
内科学
危险系数
长春瑞滨
肿瘤科
乳腺癌
化疗
艾瑞布林
吉西他滨
转移性乳腺癌
癌症
外科
胃肠病学
置信区间
顺铂
作者
Aditya Bardia,Sara A. Hurvitz,Sara M. Tolaney,Delphine Loirat,Kevin Punie,Mafalda Oliveira,Adam Brufsky,Sagar Sardesai,Kevin Kalinsky,Amelia Zelnak,Robert Weaver,Tiffany A. Traina,Florence Dalenc,Philippe Aftimos,Filipa Lynce,Sami Diab,Javier Cortés,Joyce O’Shaughnessy,Véronique Dièras,Cristiano Ferrario
标识
DOI：10.1056/nejmoa2028485
摘要
Progression-free and overall survival were significantly longer with sacituzumab govitecan than with single-agent chemotherapy among patients with metastatic triple-negative breast cancer. Myelosuppression and diarrhea were more frequent with sacituzumab govitecan. (Funded by Immunomedics; ASCENT ClinicalTrials.gov number, NCT02574455; EudraCT number, 2017-003019-21.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
BowieHuang
无极微光
shhoing
Jared
欣慰元蝶
香蕉诗蕊
pluto
JJJ
Zx_1993
star
eric888
子车茗
VDC
想吃螺蛳粉
昏睡的蟠桃
小青椒
arizaki7
丰知然
玄风
hovumath
风吹麦田
皮皮
风中冰香
皖公网安备34019202002308
